Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma
Myc, a pleiotropic transcription factor that is deregulated and/or overexpressed in most human cancers, instructs multiple extracellular programs that are required to sustain the complex microenvironment needed for tumor maintenance, including remodeling of tumor stroma, angiogenesis, and inflammat...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-11-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558611800953 |
id |
doaj-0835c3012534466eb006497aefc8025d |
---|---|
record_format |
Article |
spelling |
doaj-0835c3012534466eb006497aefc8025d2020-11-25T00:52:33ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022011-11-0113111093110010.1593/neo.11980Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for InsulinomaLaura Soucek0Joseph J. Buggy1Roderik Kortlever2Shanthi Adimoolam3Helena Allende Monclús4Maria Teresa Salcedo Allende5Lamorna Brown Swigart6Gerard I. Evan7Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco San Francisco CA USAPharmacyclics, Inc Sunnyvale CA USADepartment of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco San Francisco CA USAPharmacyclics, Inc Sunnyvale CA USAVall d’Hebron Institute of Oncology Barcelona SpainVall d’Hebron Institute of Oncology Barcelona SpainDepartment of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco San Francisco CA USADepartment of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco San Francisco CA USA Myc, a pleiotropic transcription factor that is deregulated and/or overexpressed in most human cancers, instructs multiple extracellular programs that are required to sustain the complex microenvironment needed for tumor maintenance, including remodeling of tumor stroma, angiogenesis, and inflammation. We previously showed in a model of pancreatic β-cell tumorigenesis that acute Myc activation in vivo triggers rapid recruitment of mast cells to the tumor site and that this is absolutely required for angiogenesis and macroscopic tumor expansion. More-over, systemic inhibition of mast cell degranulation with sodium cromoglycate induced death of tumor and endothelial cells in established tumors. Hence, mast cells are required both to establish and to maintain the tumors. Whereas this intimates that selective inhibition of mast cell function could be therapeutically efficacious, cromoglycate is not a practical drug for systemic delivery in humans, and no other systemic inhibitor of mast cell degranulation has hitherto been available. PCI-32765 is a novel inhibitor of Bruton tyrosine kinase (Btk) that blocks mast cell degranulation and is currently in clinical trial as a therapy for B-cell non–Hodgkin lymphoma. Here, we show that systemic treatment of insulinoma-bearing mice with PCI-32765 efficiently inhibits Btk, blocks mast cell degranulation, and triggers collapse of tumor vasculature and tumor regression. These data reinforce the notion that mast cell function is required for maintenance of certain tumor types and indicate that the Btk inhibitor PCI-32765 may be useful in treating such diseases. http://www.sciencedirect.com/science/article/pii/S1476558611800953 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Soucek Joseph J. Buggy Roderik Kortlever Shanthi Adimoolam Helena Allende Monclús Maria Teresa Salcedo Allende Lamorna Brown Swigart Gerard I. Evan |
spellingShingle |
Laura Soucek Joseph J. Buggy Roderik Kortlever Shanthi Adimoolam Helena Allende Monclús Maria Teresa Salcedo Allende Lamorna Brown Swigart Gerard I. Evan Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma Neoplasia: An International Journal for Oncology Research |
author_facet |
Laura Soucek Joseph J. Buggy Roderik Kortlever Shanthi Adimoolam Helena Allende Monclús Maria Teresa Salcedo Allende Lamorna Brown Swigart Gerard I. Evan |
author_sort |
Laura Soucek |
title |
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma |
title_short |
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma |
title_full |
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma |
title_fullStr |
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma |
title_full_unstemmed |
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma |
title_sort |
modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2011-11-01 |
description |
Myc, a pleiotropic transcription factor that is deregulated and/or overexpressed in most human cancers, instructs multiple extracellular programs that are required to sustain the complex microenvironment needed for tumor maintenance, including remodeling of tumor stroma, angiogenesis, and inflammation. We previously showed in a model of pancreatic β-cell tumorigenesis that acute Myc activation in vivo triggers rapid recruitment of mast cells to the tumor site and that this is absolutely required for angiogenesis and macroscopic tumor expansion. More-over, systemic inhibition of mast cell degranulation with sodium cromoglycate induced death of tumor and endothelial cells in established tumors. Hence, mast cells are required both to establish and to maintain the tumors. Whereas this intimates that selective inhibition of mast cell function could be therapeutically efficacious, cromoglycate is not a practical drug for systemic delivery in humans, and no other systemic inhibitor of mast cell degranulation has hitherto been available. PCI-32765 is a novel inhibitor of Bruton tyrosine kinase (Btk) that blocks mast cell degranulation and is currently in clinical trial as a therapy for B-cell non–Hodgkin lymphoma. Here, we show that systemic treatment of insulinoma-bearing mice with PCI-32765 efficiently inhibits Btk, blocks mast cell degranulation, and triggers collapse of tumor vasculature and tumor regression. These data reinforce the notion that mast cell function is required for maintenance of certain tumor types and indicate that the Btk inhibitor PCI-32765 may be useful in treating such diseases.
|
url |
http://www.sciencedirect.com/science/article/pii/S1476558611800953 |
work_keys_str_mv |
AT laurasoucek modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT josephjbuggy modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT roderikkortlever modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT shanthiadimoolam modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT helenaallendemonclus modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT mariateresasalcedoallende modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT lamornabrownswigart modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma AT gerardievan modelingpharmacologicalinhibitionofmastcelldegranulationasatherapyforinsulinoma |
_version_ |
1725241804693962752 |